Biological function of Lemur tyrosine kinase 2 (LMTK2): implications in neurodegeneration

被引:0
作者
János Bencze
Gábor Miklós Mórotz
Woosung Seo
Viktor Bencs
János Kálmán
Christopher Charles John Miller
Tibor Hortobágyi
机构
[1] University of Debrecen,Division of Neuropathology, Institute of Pathology, Faculty of Medicine
[2] King’s College London,Department of Basic and Clinical Neuroscience, Institute of Psychiatry Psychology and Neuroscience
[3] University of Szeged,Department of Psychiatry, Faculty of Medicine
[4] MTA-DE Cerebrovascular and Neurodegenerative Research Group,Department of Pathology, Faculty of Medicine
[5] University of Szeged,Department of Old Age Psychiatry, Institute of Psychiatry Psychology and Neuroscience
[6] King’s College London,undefined
来源
Molecular Brain | / 11卷
关键词
Alzheimer’s disease; Axonal transport; LMTK2; Neurodegeneration; Tau;
D O I
暂无
中图分类号
学科分类号
摘要
Neurodegenerative disorders are frequent, incurable diseases characterised by abnormal protein accumulation and progressive neuronal loss. Despite their growing prevalence, the underlying pathomechanism remains unclear. Lemur tyrosine kinase 2 (LMTK2) is a member of a transmembrane serine/threonine-protein kinase family. Although it was described more than a decade ago, our knowledge on LMTK2’s biological functions is still insufficient. Recent evidence has suggested that LMTK2 is implicated in neurodegeneration. After reviewing the literature, we identified three LMTK2-mediated mechanisms which may contribute to neurodegenerative processes: disrupted axonal transport, tau hyperphosphorylation and enhanced apoptosis. Moreover, LMTK2 gene expression is decreased in an Alzheimer’s disease mouse model. According to these features, LMTK2 might be a promising therapeutic target in near future. However, further investigations are required to clarify the exact biological functions of this unique protein.
引用
收藏
相关论文
共 482 条
  • [1] Brookmeyer R(2007)Forecasting the global burden of Alzheimer’s disease Alzheimers Dement 3 186-191
  • [2] Johnson E(2017)Amyotrophic lateral sclerosis Nat Rev Dis Primers 3 17071-174
  • [3] Ziegler-Graham K(2017)Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria Amyotroph Lateral Scler Front Degener 18 153-75
  • [4] Arrighi HM(2013)The global prevalence of dementia: a systematic review and metaanalysis Alzheimer’s and Dementia 9 63-2844
  • [5] Hardiman O(2015)Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimer’s disease Mol Brain 8 6-1158
  • [6] Al-Chalabi A(2014)Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia F1000Research 3 108-652
  • [7] Chio A(2014)Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer’s disease: association with cognitive impairment Neurobiol Aging 35 2836-148
  • [8] Corr EM(2016)Synaptic proteins predict cognitive decline in Alzheimer’s disease and Lewy body dementia Alzheimers Dement 12 1149-110
  • [9] Logroscino G(2017)Clinical and neuropathological characteristics of dementia with Lewy bodies [A Lewy-testes demencia klinikai és neuropatológiai jellemzői] Orv Hetil 158 643-2782
  • [10] Robberecht W(2015)Depression and synaptic zinc regulation in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia Am J Geriatr Psychiatry 23 141-49612